脓毒症患者基于降钙素原指导抗生素策略
|
摘要
目的:探讨降钙素原(PCT)指导脓毒症患者进行抗生素应用的临床价值。方法:回顾性分析84例脓毒症患者的临床资料,根据其是否应用降钙素原检测,将其分为对照组(n=40)以及PCT组(n=44)。对比两组患者的治疗结果、抗生素应用时间、重症监护室(ICU)住院时间和不良反应发生情况。结果:两组患者治疗结果差异无统计学意义(P>0.05);PCT组患者抗生素应用时间、ICU住院时间均短于对照组,不良反应发生率低于对照组,差异具有统计学意义(P<0.05)。结论:应用PCT对脓毒症患者的抗感染治疗进行指导,可减少抗生素应用,缩短患者的ICU住院时间,同时可减少患者抗生素所致不良反应的发生。
Objective:To investigate the clinical value of procalcitonin(PCT) in guiding antibiotic use in sepsis patients.Methods:Retrospectively analyzed the clinical data of 84 cases of spesis patients,according to whether to apply PCT divided all the patients into the control group(n=40) and the PCT group(n=44).Observed the results of treatment, the antibiotic use time, the duration time of(ICU) hospitalization and the occurrence of adverse reactions of the two groups. Results: There was no significant difference in the treatment results of the two groups(P>0.05); the antibiotic application time and the hospitalization time of ICU in the PCT group were shorter than the control group, and the incidence of adverse reactions was lower than the control group, the difference was statistically significant(P< 0.05).Conclusion:The use of PCT to guide the anti-infection treatment of sepsis patients can reduce the use of antibiotics, shorten the hospitalization time of ICU, and reduce the incidence of adverse reactions caused by antibiotics.
Objective:To investigate the clinical value of procalcitonin(PCT) in guiding antibiotic use in sepsis patients.Methods:Retrospectively analyzed the clinical data of 84 cases of spesis patients,according to whether to apply PCT divided all the patients into the control group(n=40) and the PCT group(n=44).Observed the results of treatment, the antibiotic use time, the duration time of(ICU) hospitalization and the occurrence of adverse reactions of the two groups. Results: There was no significant difference in the treatment results of the two groups(P>0.05); the antibiotic application time and the hospitalization time of ICU in the PCT group were shorter than the control group, and the incidence of adverse reactions was lower than the control group, the difference was statistically significant(P< 0.05).Conclusion:The use of PCT to guide the anti-infection treatment of sepsis patients can reduce the use of antibiotics, shorten the hospitalization time of ICU, and reduce the incidence of adverse reactions caused by antibiotics.
引文
[1]中国医师协会急诊医师分会,中国研究型医院学会休克与脓毒症专业委员会.中国脓毒症/脓毒性休克急诊治疗指南(2018)[J].临床急诊杂志,2018(9):1~21.
[2]郁彬,费爱华.药物监测美罗培南对脓毒症临床治疗效果的影响[J].临床误诊误治,2018,31(6):76~80.
[3]杨建坤,赵丽.血管活性药物治疗脓毒症休克的研究进展[J].实用医学杂志,2018,34(11):1808~1811.
[4]马青变,郑亚安.脓毒症早期抗感染治疗策略[J]中国医刊,2017,52(7):8~11.
[5]冯燕燕,谢媛媛,汪艳平,等.基于“药物-靶点-通路”网络的血必净注射液治疗脓毒症分子调控机制[J].药学学报,2017,52(4):556~562.
[6]顾鹏,周世文.以降钙素原指导脓毒症患者抗菌药物应用的Meta分析[J].中国药房,2017,28(6):791~795.
[7]张丹,卜一珊.临床药师对脓毒症重症肺炎患儿抗感染治疗的药学监护[J].儿科药学杂志,2016,22(8)40~43.
[8]李文雄.脓毒症患者抗菌药物的个体化治疗[J]中国感染与化疗杂志,2016,16(4):515~520.
[2]郁彬,费爱华.药物监测美罗培南对脓毒症临床治疗效果的影响[J].临床误诊误治,2018,31(6):76~80.
[3]杨建坤,赵丽.血管活性药物治疗脓毒症休克的研究进展[J].实用医学杂志,2018,34(11):1808~1811.
[4]马青变,郑亚安.脓毒症早期抗感染治疗策略[J]中国医刊,2017,52(7):8~11.
[5]冯燕燕,谢媛媛,汪艳平,等.基于“药物-靶点-通路”网络的血必净注射液治疗脓毒症分子调控机制[J].药学学报,2017,52(4):556~562.
[6]顾鹏,周世文.以降钙素原指导脓毒症患者抗菌药物应用的Meta分析[J].中国药房,2017,28(6):791~795.
[7]张丹,卜一珊.临床药师对脓毒症重症肺炎患儿抗感染治疗的药学监护[J].儿科药学杂志,2016,22(8)40~43.
[8]李文雄.脓毒症患者抗菌药物的个体化治疗[J]中国感染与化疗杂志,2016,16(4):515~520.